List of Excipients in Branded Drug ARTESUNATE

« Back to Dashboard

Artesunate Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 25, 2026

Artesunate has limited opportunity for new-molecule patent protection because its core composition is long established. The strongest commercial opportunities are in formulation engineering, supply reliability, pediatric and field-use presentations, fixed-dose combinations, and manufacturing platforms. In the United States, Artesunate for Injection is an FDA-approved severe-malaria treatment marketed by Amivas, with orphan-drug exclusivity expected to run through approximately 2027 if maintained from its 2020 approval date.[1,2]

What excipients are used in approved artesunate products?

The most important commercial artesunate formulation is the injectable product for severe malaria. Artesunate is hydrolytically unstable in aqueous solution, so the marketed U.S. product is supplied as a sterile powder for reconstitution rather than as a ready-to-use liquid.[1]

Product type	Typical excipient strategy	Primary formulation objective
Artesunate for injection	Arginine, sodium bicarbonate, sterile water for reconstitution	Improve dissolution and create a suitable alkaline reconstitution environment
Oral artesunate tablets	Tablet filler, binder, disintegrant, lubricant, film coating	Stabilize the active ingredient and support rapid disintegration
Artesunate-amodiaquine	Excipients selected for separate or combined API compatibility	Maintain dose uniformity and protect against moisture
Artesunate-mefloquine	Conventional solid-dose excipients with compatibility controls	Achieve acceptable dissolution for both APIs
Artesunate-pyronaridine	Bilayer or co-formulated tablet excipients	Control dose uniformity and dissolution across two active ingredients
Rectal artesunate	Suppository or compressed dosage-form base	Enable pre-referral treatment when injection is unavailable

The U.S. injectable label identifies arginine and sodium bicarbonate as formulation components. Arginine supports solubilization, while sodium bicarbonate helps establish the alkaline pH required for reconstitution.[1] The formulation is administered soon after preparation because artesunate stability declines in solution.

The excipient strategy is therefore driven by three technical constraints:

1. Artesunate has poor aqueous stability.
2. The active must dissolve rapidly at the point of use.
3. Severe-malaria treatment requires predictable dosing in hospitals and resource-limited settings.

Why are arginine and sodium bicarbonate important?

Arginine and sodium bicarbonate are not interchangeable formulation choices. Arginine can improve artesunate dissolution, while sodium bicarbonate adjusts the reconstitution environment. Changing either component can affect:

• Reconstitution time
• Final pH
• Artesunate degradation
• Visible and subvisible particulates
• Injection tolerability
• Container compatibility
• Assay and impurity profiles

A reformulation that replaces arginine with another solubilizer may require comparative stability, extractables and leachables, particulate, sterility, and pharmacokinetic support. A new excipient system could also create composition-of-matter or formulation patent opportunities, although the commercial value depends on whether the product gains regulatory or procurement advantages.

What formulation patents protect artesunate products?

Artesunate’s original active-ingredient protection is no longer commercially meaningful in major markets. The molecule was developed decades ago, and basic composition claims would generally have expired. Current protection is more likely to involve:

• Specific injectable compositions
• Lyophilized or sterile powder presentations
• Stabilized artesunate solutions
• Fixed-dose combinations
• Pediatric dispersible tablets
• Rectal delivery systems
• Manufacturing and purification processes
• Container-closure systems
• Specific dosing methods or severe-malaria treatment protocols

The most valuable formulation claim would cover a stable, ready-to-use or extended-use injectable artesunate product that avoids the short in-use window of conventional reconstituted formulations. Such a claim would need to distinguish prior systems using alkaline buffers, amino-acid solubilizers, surfactants, cyclodextrins, or other stabilizers.

How strong is the artesunate patent estate?

The estate is structurally weaker than the patent estates for newer antimalarial products because the active ingredient is old and widely manufactured. Commercial strength is concentrated in product execution rather than molecule exclusivity.

Protection category	Likely strength	Commercial relevance
Artesunate active ingredient	Low	Core chemical protection is historically expired
Conventional tablet formulation	Low to moderate	Design-around risk is high
Injectable powder with arginine and bicarbonate	Moderate	Relevant where regulatory approval depends on the specific product
Ready-to-use injectable formulation	Potentially high	Could address a major clinical and operational limitation
Fixed-dose combination	Moderate	Claims may protect ratios, release profiles, and stability
Pediatric dispersible formulation	Moderate	Procurement and adherence advantages may support differentiation
Manufacturing process	Moderate	Important if purity, yield, or impurity control is difficult to reproduce
Method-of-use claims	Low to moderate	Narrower claims may remain relevant to dosing or treatment settings

Patent value should be assessed at the jurisdiction and product level. A patent covering a formulation may not prevent sale of a different artesunate formulation, and a process patent may be difficult to enforce against an imported finished product without strong evidence of process use.

When does artesunate lose exclusivity in the United States?

The original artesunate molecule does not have meaningful remaining exclusivity. The FDA approved Artesunate for Injection, 110 mg, from Amivas in 2020 for the treatment of severe malaria in adults and children.[1,2]

The product received orphan-drug designation. Orphan-drug exclusivity generally prevents FDA approval of the same drug for the same indication for seven years after approval, subject to statutory exceptions.[2,3] On that basis, the principal U.S. regulatory exclusivity period is expected to extend to approximately 2027.

U.S. milestone	Date or status
FDA approval of Artesunate for Injection	2020
Dosage form	Sterile powder for injection
Strength	110 mg per vial
Sponsor	Amivas LLC
Orphan-drug exclusivity	Approximately seven years from approval
Expected end of orphan exclusivity	Approximately 2027
Basic artesunate molecule	Historical protection expired
Orange Book relevance	Product-specific patent and exclusivity listings must be checked against the current FDA database

Orphan exclusivity is not the same as patent protection. It does not prevent all competing products. It may not block a different drug, a different indication, or a product that qualifies under an applicable statutory exception.

What is the Orange Book status of Artesunate for Injection?

The FDA Orange Book is the primary U.S. source for approved drug products, therapeutic equivalence evaluations, patents, and relevant exclusivity data.[3] Artesunate for Injection should be reviewed by reference to the approved NDA and current Orange Book listings rather than by assuming that all Amivas formulation rights are publicly listed.

The strategic implications are:

• A listed patent can create a formal Paragraph IV pathway for an ANDA applicant.
• An unlisted or expired patent may still have commercial relevance outside the ANDA framework.
• Orphan exclusivity can remain relevant even where no blocking patent is listed.
• A generic injectable applicant must address sterile manufacturing, drug-product equivalence, and supply-chain requirements in addition to patent issues.

The practical patent risk for a U.S. generic is likely to be lower than the regulatory and manufacturing burden. Injectable products face demanding requirements for sterility assurance, particulate control, container closure, reconstitution performance, and process validation.

Which companies are challenging artesunate exclusivity?

No major, widely reported U.S. Paragraph IV litigation campaign has established a competitive challenge to Artesunate for Injection comparable to the litigation surrounding large commercial products. The likely competitive route is an ANDA or other abbreviated pathway after relevant exclusivity expires, rather than a high-profile patent challenge during the orphan period.

Potential challengers include:

• Sterile injectable generic manufacturers
• Contract development and manufacturing organizations
• Public-health suppliers seeking regional tenders
• Manufacturers of artesunate combination products
• Companies developing alternative severe-malaria injectable presentations

The principal barrier is not only legal. A challenger must manufacture a sterile powder product, validate the reconstitution process, demonstrate pharmaceutical equivalence, and satisfy FDA inspection requirements.

What generic entry risks exist for artesunate?

Generic entry risk is highest for conventional solid oral products and lower, initially, for sterile injectable products.

Oral artesunate

Oral artesunate is widely used in combination therapy. Competitive entry is facilitated by:

• Long-established tablet technology
• Broad API availability
• Multiple global suppliers
• Existing WHO-prequalified products
• Conventional manufacturing equipment

The main risks are price compression, tender-based competition, and substitution among fixed-dose combinations.

Injectable artesunate

Injectable competition is more difficult because manufacturers must manage:

• Sterile powder filling
• Accurate vial assay
• Reconstitution performance
• API degradation
• Container closure integrity
• Particulate matter
• Supply continuity during emergency demand

A generic can potentially enter after applicable exclusivity ends even if it uses a different excipient composition. That makes formulation patents most valuable when they cover a clinically meaningful feature that is difficult to replicate, such as rapid reconstitution, improved in-use stability, or reduced degradation.

What excipient opportunities exist for artesunate injection?

The highest-value excipient opportunity is a product that reduces preparation risk without compromising stability.

Ready-to-use or extended-use liquid formulations

A stable liquid injection could eliminate reconstitution steps and reduce medication errors. The formulation would need to control hydrolysis and maintain acceptable impurity levels throughout shelf life and the in-use period.

Potential technologies include:

• pH-controlled aqueous systems
• Amino-acid solubilizers
• Cyclodextrin complexes
• Co-solvent systems
• Surfactant-assisted formulations
• Nanoparticle or lipid-based systems
• Dual-chamber containers
• On-demand reconstitution devices

The regulatory burden would be high because the formulation would differ materially from the approved powder. The commercial benefit could justify that burden in hospitals, emergency departments, military medicine, and low-resource settings.

Improved powder formulations

A lower-risk program would optimize the existing powder approach by improving:

• Cake or powder dissolution
• Vial fill accuracy
• Reconstitution time
• Moisture resistance
• Shelf life at elevated temperature
• Compatibility with alternative diluents
• Packaging for hot and humid climates

This approach can create incremental differentiation without requiring a completely new delivery system.

Alternative container systems

Dual-chamber syringes, dual-chamber vials, and prefilled reconstitution devices could have commercial value. They may reduce handling steps while preserving a dry artesunate component.

The IP opportunity may lie in the device and container system rather than the excipient itself. Claims could cover the separation of artesunate from the activating diluent, mixing sequence, dose delivery, and stability during storage.

What oral artesunate formulations are protected by intellectual property?

Oral formulation protection is more fragmented than injectable protection. Relevant claim categories include:

• Artesunate particle size
• Solid dispersion systems
• Moisture-barrier coatings
• Taste-masked pediatric tablets
• Orally disintegrating tablets
• Dispersible tablets
• Bilayer tablets
• Fixed-dose ratios
• Modified-release systems
• Impurity-control processes

The strongest commercial opportunity is usually a combination product rather than standalone artesunate. WHO recommends artemisinin-based combination therapy because monotherapy creates resistance concerns and is generally unsuitable for routine malaria treatment.[4]

Potential products include:

Combination	Commercial rationale
Artesunate-amodiaquine	Established ACT platform with public-health demand
Artesunate-mefloquine	Useful in selected markets and procurement programs
Artesunate-pyronaridine	Differentiated ACT with global regulatory and procurement relevance
Artesunate-sulfadoxine-pyrimethamine	Regionally relevant where resistance patterns permit
Artesunate-lumefantrine	Competitive with established ACT products but technically more crowded

For these products, excipient selection must account for the dissolution and stability behavior of each active ingredient. A common excipient system may produce unequal dissolution, segregation, or degradation. Bilayer or multilayer tablets can reduce incompatibility but increase manufacturing complexity.

What pediatric artesunate opportunities exist?

Pediatric formulations are a significant development area because malaria treatment requires accurate weight-based dosing and children may have difficulty swallowing conventional tablets.

Commercially attractive formats include:

• Dispersible tablets
• Orodispersible tablets
• Mini-tablets
• Sachets for reconstitution
• Rectal formulations for pre-referral treatment
• Low-strength combination tablets
• Taste-masked granules

A dispersible tablet should disperse rapidly in a small volume of water, maintain dose uniformity across pediatric strengths, and remain stable under tropical storage conditions. Taste masking is important because bitterness can reduce adherence and lead to incomplete dosing.

The strongest differentiation may come from a combined package of formulation, device, and dosing information rather than from a single excipient patent.

What manufacturing and IP barriers affect artesunate?

Artesunate manufacturing requires control of both API quality and degradation products. The main technical barriers include:

• Control of hydrolysis-related impurities
• Stereochemical and chemical purity
• Consistent particle properties
• Moisture control
• Sterile filling for injectable products
• Scale-up of lyophilization or powder processing
• Validation of reconstitution
• Stability under tropical conditions
• Reliable supply of qualified API

For injectable products, the drug substance and drug product supply chains are closely linked. A manufacturer may have freedom to operate on the final formulation but still face practical barriers if it cannot source API with consistent impurity and particle specifications.

Process patents may have greater value in markets where manufacturing know-how is difficult to reproduce. Trade secrets covering crystallization, purification, drying, and impurity removal can supplement formal patents.

What licensing deals and commercial partnerships are available?

Licensing opportunities are most credible in five areas:

1. Regional commercialization of approved artesunate products.
2. Technology transfer for sterile powder manufacturing.
3. WHO-prequalified fixed-dose combinations.
4. Pediatric dispersible and rectal formulations.
5. Ready-to-use injection or reconstitution-device technology.

A partner evaluating artesunate should separate rights into:

• API supply
• Finished-dose manufacturing
• Regulatory approvals
• Government procurement access
• Trademark rights
• Formulation patents
• Process know-how
• Device rights
• Data and dossier rights

The most valuable license is unlikely to be a broad artesunate license. It is more likely to be a narrowly defined right covering a differentiated formulation, a regional procurement channel, or a validated sterile manufacturing process.

How does artesunate compare with competing antimalarial products?

Product	Main use	Formulation competition	IP position	Commercial profile
Artesunate injection	Severe malaria	Moderate for sterile products	Old active ingredient; product-specific rights may remain	Hospital and emergency demand
Artemether injection	Severe malaria where used	Injectable manufacturing competition	Mature generic market	Alternative parenteral therapy
Artesunate-amodiaquine	Uncomplicated malaria	High tablet competition	Combination and formulation claims	Public-health procurement
Artesunate-pyronaridine	Uncomplicated malaria	Moderate to high	More recent combination-product protection may exist	Differentiated ACT segment
Artemether-lumefantrine	Uncomplicated malaria	High	Mature combination market	Large global commercial presence
Quinine injection	Severe malaria alternative	Mature injectable market	Limited active-ingredient protection	Declining preference where artesunate is available

Artesunate’s competitive advantage is clinical and operational rather than patent-based. Injectable artesunate is widely recognized as a preferred treatment for severe malaria, while oral artesunate is commercially strongest when incorporated into an approved ACT.[4,5]

What is the revenue exposure for artesunate products?

Revenue exposure is concentrated in public-sector procurement, hospital demand, and endemic-market tenders. It is less comparable to the recurring retail revenue profile of chronic-disease medicines.

Key commercial variables are:

• National malaria-program purchasing
• WHO and UNICEF procurement
• Emergency stockpiling
• Seasonal malaria incidence
• Regional treatment guidelines
• Tender pricing
• Product prequalification
• Supply reliability
• Pack size and pediatric coverage
• Manufacturing location and regulatory status

An injectable product can generate higher unit value than an oral tablet, but total volume may be lower and demand can be episodic. A company with a portfolio spanning injection, pediatric products, and ACT combinations can reduce dependence on a single procurement channel.

Key Takeaways

• Artesunate’s core molecule has no meaningful remaining new-molecule patent advantage.
• The U.S. injectable product was approved in 2020 and benefits from orphan-drug exclusivity expected to run to approximately 2027.
• Arginine and sodium bicarbonate are central to the established injectable formulation strategy.
• The strongest excipient opportunity is a stable ready-to-use injection or an improved reconstitution system.
• Oral commercial opportunities are concentrated in fixed-dose combinations and pediatric dispersible products.
• Generic risk is higher for tablets and lower initially for sterile injectables.
• Manufacturing, sterility, stability, and procurement access may matter more than patent scope.
• Licensing value is highest for differentiated formulations, sterile technology, pediatric products, and regional regulatory or procurement rights.

FAQs About Artesunate Excipient Strategy and Commercialization

Can artesunate be formulated as a ready-to-use injection?

Yes, but the formulation must control hydrolytic degradation and maintain acceptable impurity levels throughout shelf life and the in-use period. A ready-to-use product would require substantial stability and regulatory support.

Is arginine essential in every artesunate injection?

No. Arginine is used in established injectable formulations, but alternative solubilizers may be possible. Any replacement must demonstrate acceptable dissolution, stability, tolerability, and product performance.

Does artesunate have biosimilar risk?

No. Artesunate is a chemically synthesized small molecule, not a biologic. The relevant competitive risks are generic, hybrid, fixed-dose combination, and formulation competition.

Are artesunate tablets eligible for ANDA approval?

A conventional tablet may be eligible for an ANDA if an appropriate U.S. reference product and regulatory pathway exist. Combination products and products with materially different dosage forms may require a different regulatory strategy.

Which artesunate formulation has the best commercial potential?

The strongest differentiated opportunities are a stable ready-to-use injectable product, a low-cost pediatric dispersible ACT, and a robust rectal or pre-referral formulation for settings without immediate access to intravenous treatment.

References

1. U.S. Food and Drug Administration. (2020). Artesunate for injection prescribing information. Amivas LLC.

2. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. World Health Organization. (2023). Guidelines for malaria. World Health Organization.

5. World Health Organization. (2024). World malaria report 2024. World Health Organization.